Journal Questions Vioxx Absorption 2
Merck disputes the bend that those three amore attacks substantially affected the study's results.
The accession states that it "believes it is important to emphasis that the accession promptly and appropriately arise the after-effects of the VIGOR study."
"Merck accurately arise about the allowances and attainable risks of Vioxx and abundantly arise the VIGOR abstracts to the authentic and medical communities, and in the press," the annual continues.
Merck's annual aswell addition that the after-effects were "fairly and accurately described" as of a prespecified draft for analysis. The three other amore attacks happened afterwards the prespecified draft date and therefore weren't allocation of the absorption as arise in the journal, states Merck.
However, Merck stresses that it arise those amore attacks to the FDA in 2000 and 2001 and to doctors, the public, and the media.
The biologic accession adds that it abandoned again abstract of the exhausted and "looks avant-garde to accouterment a added complete response" to it.
Researcher's Statement
WebMD emailed Claire Bombardier, MD, who formed on the ancient study, for her acceptance to the journal's editorial.
Bombardier, who works at the University of Toronto, replied by email. Her statement reads:
"In acceptance to the exhausted that appeared today in the NEJM, I believe that the Vigor agenda appropriately arise the abstracts as per the prespecified plan of analysis. Events that occurred afterwards the pre authentic complete date have been about accustomed aback the FDA advising lath in February 2001. The authors of the agenda will be advancing a acceptance to the exhausted but given the absolute abridge alarm from the NEJM we acquire not had the time to accede it yet."